Sitimagene ceradenovec, a gene therapeutic for the treatment of glioma.
Ark Therapeutics Group plc is developing sitimagene ceradenovec, a herpes simplex virus thymidine kinase/ganciclovir gene therapy utilizing an adenoviral vector, for the potential treatment of glioma. Sitimagene ceradenovec is currently undergoing a phase III clinical trial in malignant glioma patients.
Düzgünes
Nejat
N
University of the Pacific, Department of Microbiology, Arthur A Dugoni School of Dentistry, 2155 Webster Street, San Francisco, CA 94115, USA. nduzgune@pacific.edu
D000818:Animals; D001932:Brain Neoplasms / Q000628:therapy*; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D015316:Genetic Therapy; D005910:Glioma / Q000628:therapy*; D006801:Humans; D013329:Structure-Activity Relationship; D013937:Thymidine Kinase / Q000493:pharmacokinetics / Q000627:therapeutic use*
D013937:Thymidine Kinase; C529697:sitimagene ceradenovec